

Reference number(s)
4517-A

## SPECIALTY GUIDELINE MANAGEMENT

### CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

Cabenuva is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

All other indications are considered experimental/investigational and not medically necessary.

##### II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: For initial requests, plasma HIV-1 RNA level (viral load) within the last 6 months.

##### III. CRITERIA FOR INITIAL APPROVAL

##### **Human immunodeficiency virus type 1 (HIV-1) infection**

Authorization of 12 months may be granted for treatment of human immunodeficiency virus type 1 (HIV-1) infection when all of the following criteria are met:

- A. Member is currently receiving a stable antiretroviral regimen.
- B. Member is virologically suppressed on the current antiretroviral regimen with HIV-1 RNA level (viral load) less than 50 copies per mL.
- C. Member has no history of treatment failure.
- D. Member has no known or suspected resistance to either cabotegravir or rilpivirine.

##### IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for treatment of human immunodeficiency virus type 1 (HIV-1) infection when the member has not experienced a virologic failure while on the requested drug, defined as two consecutive plasma HIV-1 RNA levels (viral loads) greater than or equal to 200 copies per mL.

Reference number(s)
4517-A

## V. REFERENCES

1. Cabenuva [package insert]. Durham, NC: ViiV Healthcare; February 2023.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf>. Accessed November 7, 2023.